149 related articles for article (PubMed ID: 37971239)
1. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
2. Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.
Mulubwa M; Mugabo P
Br J Clin Pharmacol; 2019 Sep; 85(9):1946-1956. PubMed ID: 31046167
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.
Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa.
van der Walt ML; Shean K; Becker P; Keddy KH; Lancaster J
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046491
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
7. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
Kengo A; Nabeemeeah F; Denti P; Sabet R; Okyere-Manu G; Abraham P; Weisner L; Mosala MH; Tshabalala S; Scholefield J; Resendiz-Galvan JE; Martinson NA; Variava E
Antimicrob Agents Chemother; 2024 May; 68(5):e0158323. PubMed ID: 38597667
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
10. Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis.
Mulubwa M; Mugabo P
Drugs R D; 2019 Sep; 19(3):289-296. PubMed ID: 31396892
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.
Bjugård Nyberg H; Draper HR; Garcia-Prats AJ; Thee S; Bekker A; Zar HJ; Hooker AC; Schaaf HS; McIlleron H; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871093
[TBL] [Abstract][Full Text] [Related]
12. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H
Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422
[TBL] [Abstract][Full Text] [Related]
13. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.
Court R; Centner CM; Chirehwa M; Wiesner L; Denti P; de Vries N; Harding J; Gumbo T; Maartens G; McIlleron H
Int J Infect Dis; 2021 Apr; 105():688-694. PubMed ID: 33684562
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
